Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003172 · ClinicalTrials.gov registry record · Phase 2

Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer

A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase

NCT00003172: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.

NCT00003172 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003172, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations and combining them with interferon alfa and G-CSF may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating patients with advanced stomach cancer.

Interventions

  • DRUG docetaxel
  • DRUG fluorouracil
  • BIOLOGICAL filgrastim
  • DRUG doxorubicin hydrochloride
  • BIOLOGICAL recombinant interferon alfa

Trial Details

FieldValue
Start Date 1997-12
Est. Completion 2004-09
Phase Phase 2
Eastern Cooperative Oncology Group

141 total trials

What the finished NCT00003172 record still lists

NCT00003172 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.

NCT00003172 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003172 about?

NCT00003172 is a clinical study titled "Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations and combining them with interferon alfa and G-CSF may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness...

What is the current status of trial NCT00003172?

This trial is currently completed. It is a Phase 2 study. The study started on 1997-12. Estimated completion is 2004-09.

What interventions are being tested in trial NCT00003172?

The interventions under investigation include: docetaxel (DRUG), fluorouracil (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), recombinant interferon alfa (BIOLOGICAL).

Who is sponsoring clinical trial NCT00003172?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003172, the US trial registry maintained by the National Library of Medicine. NCT00003172 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.